| Title |
Role of biological targeted therapies in gastroenteropancreatic neuroendocrine tumours
|
|---|---|
| Published in |
Endocrine, August 2011
|
| DOI | 10.1007/s12020-011-9513-y |
| Pubmed ID | |
| Authors |
Kein-Leong Yim |
| Abstract |
Approximately two-thirds of neuroendocrine tumours (NET) occur in the gastrointestinal tract and over 60% present with metastases. With greater insight into molecular pathways involved in tumour progression, opportunities are presented for the use of targeted therapies in NET. Although a wide array of targeted agents has been investigated, only a handful has emerged as forerunners from recent clinical trials. This literature review focuses on the use of anti-angiogenic monoclonal antibody bevacizumab, as well as small molecule inhibitors sunitinib and everolimus. |
Mendeley readers
The data shown below were compiled from readership statistics for 8 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 8 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Bachelor | 3 | 38% |
| Researcher | 1 | 13% |
| Other | 1 | 13% |
| Student > Doctoral Student | 1 | 13% |
| Unknown | 2 | 25% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 4 | 50% |
| Agricultural and Biological Sciences | 1 | 13% |
| Business, Management and Accounting | 1 | 13% |
| Unknown | 2 | 25% |